Renaissance Capital logo

VRNA News

US IPO Weekly Recap: Floor & Décor pops 53%, Carvana skids 26%

FND

9 IPOs priced deals this week. This brings April’s total to 20, making it the busiest month of the past 22. These 20 pricings were almost enough to double the count for the year, raising that number to 45. Five biotechs priced in April, doubling the total for the year after just three biotechs priced in the 1Q17. The deals this week included the best and worst first day...read more

Verona Pharma prices IPO at $13.50

VRNA

Verona Pharma, which is developing inhaled treatments for respiratory diseases, raised $78 million by offering 5.8 million shares at $13.50, in line with the expected price of $13.49. Verona Pharma plans to list on the Nasdaq under the symbol VRNA. Jefferies and Stifel acted as lead managers on the deal....read more

US IPO Week Ahead: Cloudera leads pack of 8 deals

CLDR

A whopping eight deals are on the calendar for the week ahead after a flurry of launches hit Monday. The month's 11 IPOs already make it the most active year-to-date, but if all eight April deals on the US IPO calendar price, April would be busier than all but one month (Oct 2016; 19 IPOs) in...read more

Respiratory biotech Verona Pharma sets terms for $75 million US IPO

VRNA

Verona Pharma, which is developing inhaled treatments for respiratory diseases, announced terms for its US IPO on Tuesday. The biotech currently trades on London's AIM market under the symbol VRP, and plans to list on the Nasdaq under the symbol VRNA. The London, UK-based company is set to offer shares representing 5.6 million ADSs; at its converted AIM price of $13.49, the...read more